Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Blood-tests that screen for many kinds of cancer would revolutionize healthcare. Most are being developed for use with Illumina's gene sequencers, so the FTC fears that Illumina's deal to acquire test developer Grail would harm competition in the nascent field.

The FTC Wants to Block Illumina's Deal For Grail

SAN DIEGO--(BUSINESS WIRE)--Illumina commits to pursuing GRAIL acquisition to accelerate access to breakthrough multi-cancer early detection blood test.

Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

10x Genomics is powering the next generation of biotech research.

2,500% Returns? This Stock Is Like Buying Illumina in 2007

Intuitive Surgical

Teladoc

From genomics to virtual care, these stocks should be huge long-term winners.

3 Top Stocks to Buy to Profit From the Healthcare Revolution

Boston Scientific

We think that Boston Scientific currently is a better pick compared to Illumina. BSX stock trades at about 5.6x trailing revenues, compared to around 18.8x for ILMN.

Here's Why We Believe Boston Scientific Is A Better Pick Over Illumina Stock

Bionano Genomics

Fulgent Genetics

Gene science will continue to drive the healthcare sector to new heights.

Buy These 3 Stocks to Cash In on the Genomics Revolution

SAN DIEGO--(BUSINESS WIRE)--Illumina announced that John W. Thompson will be appointed as the Company's new Chair of the Board following Jay Flatley's decision to step down.

Illumina Announces Board Changes

Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of products.

Why You Should Hold on to Illumina (ILMN) Stock for Now

Oversubscribed Financing to Build World's First High-Density DNA-Based Memory Chip Oversubscribed Financing to Build World's First High-Density DNA-Based Memory Chip

Iridia Raises $24 Million in Series B Funding

Amazon

MercadoLibre

Spotify

Tesla

We are pleased to announce that we added Scotland-based investment firm Baillie Gifford (Trades, Portfolio) to our Premium list of gurus. According to top 10 holdings statistics, the firm's top five holdings as of the December 2020 filing date are Tesla Inc. (NASDAQ:TSLA), Amazon.com Inc. (NASDAQ:AMZN), MercadoLibre Inc. (NASDAQ:MELI), Illumina Inc. (NASDAQ:ILMN) and Spotify Technology SA (NYSE:SPOT).

Top 5 Holdings of Investment Firm Baillie Gifford

COMPASS Pathways

Johnson & Johnson

Pfizer

ResMed

Thermo Fisher Scientific

These steady, strong healthcare stocks are great picks for investors to buy and hold onto for at least the next five years. The post 7 Healthcare Stocks to Buy and Hold for the Long Term appeared first on InvestorPlace.

7 Healthcare Stocks to Buy and Hold for the Long Term

Illumina's (ILMN) coverage for pregnant women under the age of 35 will provide access of NIPT to thousands of women with minimal financial impact.

Illumina's (ILMN) Expanded NIPT Coverage Study Outcome Favorable

SAN DIEGO--(BUSINESS WIRE)--A new study shows that the cost of offering NIPT in all pregnancies is minimal whereas this screening method is known to produce better outcomes

Illumina and Harvard Pilgrim Health Care Real-World Evidence Study Demonstrates Cost-Effectiveness of Offering NIPT to All Pregnant Women

Adaptive Biotechnologies

Amgen

BioNTech SE

Moderna

Microsoft

The confluence of healthcare and technology will send many biotech stocks soaring over the next decade.

Why You Should Own Biotech Stocks Now

Its future is bright, but growth catalysts are uncertain in the short term.

Should You Buy Illumina Stock in March?

Illumina and R-Pharm's in-vitro diagnostics platform registration will drive the expansion of Next Generation Sequencing-based clinical diagnostics across Russia.

Illumina (ILMN) NGS-Based Platform Approved for Use in Russia

Illumina is strategically positioning itself as a key player in high growth segments of the genomic revolution. Illumina's metrics show that it is another perennially high priced stock.

Illumina: Gene Sequencing Leader In The Golden Age Of Genetics

This unlikely choice meets several of his criteria.

This Is the Stock Warren Buffett Should Have Been Buying

Illumina (ILMN) closed the most recent trading day at $398.85, moving -0.19% from the previous trading session.

Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know

SAN DIEGO--(BUSINESS WIRE)--Illumina and R-Pharm received medical device registration in Russia of the NextSeq 550Dx platform and reagent kits as well as MiSeq Dx reagents

Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia

Oracle

Virgin Galactic

Citrix Systems

Danaher

DocuSign

With the trading day about halfway over, the broad markets have not made up their minds on a direction for the day.

Microsoft, Oracle, Tesla, Virgin Galactic and More Wednesday Afternoon Analyst Calls

Cowen

Illumina, Inc. (ILMN) CEO Francis deSouza Presents at Cowen 41st Annual Health Care Conference (Transcript)

Alibaba

Baxter

Equifax

Generation Investment Management, the firm co-founded by Al Gore (Trades, Portfolio) and David Blood, disclosed this month that its top four buys during the fourth quarter of 2020 included a new position in Alibaba Group Holding Ltd. (NYSE:BABA) and boosts to its Equifax Inc. (NYSE:EFX), Baxter International Inc. (NYSE:BAX) and Illumina Inc. (NASDAQ:ILMN) holdings.

Top 4 4th-Quarter Buys of Al Gore's Generation Investment Management

SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- A judge in the U.S. District Court for the Northern District of California has granted MGI's motion for leave to amend to add a new inequitable conduct defense of patent infringement lawsuit that Illumina filed against MGI in February 2020...

US Court Grants MGI's Motion to Amend in Suit Against Illumina

TÜBINGEN, Germany--(BUSINESS WIRE)--Illumina partners with the University of Tubingen to study the value of whole-genome sequencing as a diagnostic for patients with genetic diseases

News for Illumina Stock (ILMN)